Clinical Trial Update: Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on bevacizumab nasal spray for epistaxis in hereditary hemorrhagic telangiectasia across Phase 2 and Phase 3. The study has been terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Bevacizumab nasal spray (Bevacizumab)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 2, Phase 3 | Status: TERMINATED